These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30567880)

  • 1. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes.
    Johns DG; LeVoci L; Krsmanovic M; Lu M; Hartmann G; Xu S; Wang SP; Chen Y; Bateman T; Blaustein RO
    Drug Metab Dispos; 2019 Mar; 47(3):227-233. PubMed ID: 30567880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
    Johns DG; Wang SP; Rosa R; Hubert J; Xu S; Chen Y; Bateman T; Blaustein RO
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00543. PubMed ID: 31832204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anacetrapib: a new weapon against dyslipidemia.
    Aperis G; Paliouras C; Tsampikaki E; Papakonstantinou N; Alivanis P
    Curr Clin Pharmacol; 2011 Nov; 6(4):227-35. PubMed ID: 22082322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.
    Hartmann G; Kumar S; Johns D; Gheyas F; Gutstein D; Shen X; Burton A; Lederman H; Lutz R; Jackson T; Chavez-Eng C; Mitra K
    Drug Metab Dispos; 2016 Mar; 44(3):428-34. PubMed ID: 26712818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
    Gotto AM; Moon JE
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):955-63. PubMed ID: 23030283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trials and Tribulations of CETP Inhibitors.
    Tall AR; Rader DJ
    Circ Res; 2018 Jan; 122(1):106-112. PubMed ID: 29018035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
    Krishna R; Gheyas F; Liu Y; Hagen DR; Walker B; Chawla A; Cote J; Blaustein RO; Gutstein DE
    Clin Pharmacol Ther; 2017 Nov; 102(5):832-840. PubMed ID: 28380664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Apr; 19(6):611-615. PubMed ID: 29498299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Teramoto T; Daida H; Ikewaki K; Arai H; Maeda Y; Nakagomi M; Shirakawa M; Watanabe Y; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Blaustein RO
    Atherosclerosis; 2017 Jun; 261():69-77. PubMed ID: 28478132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
    Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM
    J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.